FDA authorizes ZYN modified-risk claims for 20 variants in US
The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on 11 November 2026, allowing Philip Morris to state lower disease risks than cigarettes for those products only.
Key points
- The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on 11 November 2026.
- The permitted claim covers lower risks of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis versus cigarettes.
- The FDA reviewed company applications and evidence under Section 911 of the Federal Food, Drug, and Cosmetic Act.
- The authorization covers the named variants and wording only and does not mean the products are risk-free.
On this page
- Claims are limited to six named conditions
- Section 911 review covered adults who switched from cigarettes
- The order does not declare the products risk-free
- The decision supports Philip Morris’s smoke-free expansion
- Manufacturers should read the order as a wording limit, not a category approval
- What happens next
- Questions readers ask
The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on Wednesday 11 November 2026, letting Philip Morris International make specified lower-risk claims against cigarettes in the US.
The order covers those 20 variants and specific wording only. It does not apply to other ZYN products or to claims the agency has not reviewed.
Claims are limited to six named conditions
The permitted statement refers to lower risks of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis compared with cigarette use, according to the report.
Philip Morris may use that comparison in the US market for the approved products. The authorization sets the boundary of what the company can say, not a general licence to describe the range as low risk.
Section 911 review covered adults who switched from cigarettes
The FDA decision followed a review of company applications and scientific evidence submitted under Section 911 of the Federal Food, Drug, and Cosmetic Act.
The evidence cited included information on adults who smoked cigarettes and later began using ZYN pouches. The source does not report how many applications were filed, how many were refused, or what data the agency weighed against the company’s submissions.
The order does not declare the products risk-free
Nicotine remains addictive, and the authorization is not an endorsement for non-smokers, the report states.
That distinction matters for labelling and advertising review: a modified-risk order permits a comparative claim, while a statement that the products carry no risk would fall outside it.
The decision supports Philip Morris’s smoke-free expansion
The authorization gives the company a permitted regulatory framework for communicating the cigarette comparison in the US, while restricting it to the authorized variants and wording.
Smoke-free products sit at the centre of Philip Morris International’s strategy of expanding beyond combustible cigarettes, according to the report. The company’s ISIN is listed as US7181721090.
Manufacturers should read the order as a wording limit, not a category approval
Analysis: the order applies product by product and claim by claim, so compliance work centres on matching advertising copy, packaging inserts and retail materials to the authorized wording for each variant.
For suppliers, the practical effect is that comparative risk language has a documented US reference point for one brand’s pouches, while the same language for other products remains unauthorized unless separately reviewed.
What happens next
Philip Morris can now deploy the permitted claim for the 20 variants in the US. The source does not state an expiry date for the order, any transition period for existing materials, or a date for further FDA decisions on ZYN applications.
| Item | Detail |
|---|---|
| Decision date | 11 November 2026 |
| Products covered | 20 ZYN nicotine pouch variants |
| Legal basis | Section 911, Federal Food, Drug, and Cosmetic Act |
| Conditions named in the permitted claim | Mouth cancer, heart disease, lung cancer, stroke, emphysema, chronic bronchitis |
| Company | Philip Morris International Inc., ISIN US7181721090 |
Questions readers ask
Does the FDA order mean ZYN pouches are risk-free?
No. The report states the order does not mean the products are risk-free or that nicotine use is safe, and that nicotine remains addictive.
Which ZYN products does the authorization cover?
The order covers 20 ZYN nicotine pouch variants and limits claims to those authorized variants and wording.
Sources
18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information



